Raymond E. Cabillot Sells 3,096 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,096 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $50.13, for a total transaction of $155,202.48. Following the sale, the director now directly owns 279,787 shares in the company, valued at approximately $14,025,722.31. This represents a 1.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Pro-Dex Price Performance

PDEX traded up $0.57 during trading on Thursday, reaching $49.98. 15,749 shares of the stock were exchanged, compared to its average volume of 22,119. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44. The company has a market capitalization of $162.98 million, a price-to-earnings ratio of 24.87 and a beta of 0.68. Pro-Dex, Inc. has a 1 year low of $16.84 and a 1 year high of $59.60. The business’s 50 day moving average price is $40.13 and its two-hundred day moving average price is $39.75.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, equities research analysts anticipate that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Hedge Funds Weigh In On Pro-Dex

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDEX. FMR LLC grew its position in shares of Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the last quarter. Geode Capital Management LLC lifted its stake in Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares in the last quarter. Ritholtz Wealth Management acquired a new stake in Pro-Dex during the 4th quarter valued at $572,000. Finally, Bank of New York Mellon Corp purchased a new position in Pro-Dex during the fourth quarter worth $202,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Pro-Dex from a “buy” rating to a “hold” rating in a research report on Wednesday, March 12th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.